2007 LAM Foundation Lymphangioleiomyomatosis International Research Conference(NHLBI)
2007 LAM Foundation Lymphangioleiomyomatosis International Research Conference
April 20–22, 2007 •Cincinnati, OH
Agenda
| Friday, April 20 |
|
| Session I: Origins of LAM Session Chair: Joel Moss, Ph.D., M.D., National Heart, Lung, and Blood Institute |
|
| 7:55 a.m. | Welcome
Frank McCormack, M.D. |
| 8:00 a.m. | Comments by Chair and Patient Intro |
| Comments by LAM Patient Eden Pontz | |
| 8:10 a.m. | LAM Overview Frank McCormack, M.D. |
| 8:40 a.m. | Mechanisms of Lymphangiogenesis Kari Alitalo, M.D., Ph.D. |
| 9:20 a.m. | Melanocyte Markers and the Origins of LAM Raymond Boissy, Ph.D. |
| 10:05 a.m. | Evidence for an Extra-Pulmonary Origin of LAM Elizabeth Henske, M.D. |
| 11:15 a.m. | Cell Signaling via Nuclear Hormone Receptors Ellis Levin, M.D. |
| 11:45 a.m. | Abstract 1 |
| Session II: Opportunities and Obstacles for Treating LAM Patients Session Chair: Aristotelis Astrinidis, Ph.D., Fox Chase Cancer Center |
|
| 1:00 p.m. | Comments by Chair and Patient Intro |
| 1:05 p.m. | Comments by LAM Patient Heather Telford |
| 1:15 p.m. | Promises and Pitfalls of Targeting mTOR/AKT in the Clinic Gordon Mills, M.D. |
| 1:55 p.m. | 2003 Rapamycin Clinical Trial John Bissler, M.D. |
| 2:25 p.m. | LAM Trials: A Pharmaceutical Perspective David Rodman, M.D. |
| 3:15 p.m. | Preclinical Studies with Rapamycin Analogs David Kwiatkowski, M.D., Ph.D. |
| 3:45 p.m. | Activation of TSC2 by LKB1/AMPK Signaling: Therapeutic Uses of
Metformin
Lewis Cantley, Ph.D. |
| 4:15 p.m. | Statins as Therapeutic Agents for LAM Geraldine Finlay, M.D. |
| 4:45 p.m. | Abstract 2 |
| 5:00 p.m. | Abstract 3 |
| 5:15 p.m. | Abstract 4 |
| 6:30 p.m. | Welcome and Introductions Leslie Sullivan-Stacey, President and CEO |
| 7:40 p.m. |
Conference Address |
| 8:00 p.m. |
Award Presentations Frank McCormack, M.D. Leslie Sullivan-Stacey, President and CEO |
| 8:25 p.m. | LAM Research Overview Frank McCormack, M.D., Scientific Director |
| Saturday, April 21 |
|
| Session III: The Place of TSC1/TSC2 in the World of Cell Signaling Session Chair: Vera Krymskaya, Ph.D., University of Pennsylvania |
|
| 8:00 a.m. | Comments by Chair and Patient Intro |
| 8:05 a.m. | Comments by LAM Patient Audrey Buckland |
| 8:10 a.m. | Overview of P13K Signaling Pier-Palo Pandolfi, M.D., Ph.D. |
| 8:50 a.m. | Nutrient Sensing and TSC George Thomas, M.D. |
| 9:20 a.m. | Redox Regulation of mTOR Signaling David Sabatini, M.D., Ph.D. |
| 10:20 a.m. | Hypoxia Inducible Factor 1 Alpha is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif
Andrew Tee, Ph.D. |
| 10:50 a.m. | TSC Cross-Talk with Other Signaling Pathways Brendan Manning, Ph.D. |
| 11:05 | Abstract 5 |
| Abstract 6 | |
| Abstract 7 | |
| 11:20 a.m. | Cell Signaling Pathways that Target Hamartin Mien-Chie Hung, M.D., Ph.D. |
| Session IV: Regulation of Cell Proliferation Session Chair: Blanca Camoretti-Mercado, Ph.D., University of Chicago |
|
| 2:00 p.m. | Comments by Chair and Patient intro |
| 2:05 p.m. | Comments by LAM Patient Ashley Tollett |
| 2:10 p.m. | Regulation of HIF and Cell Growth Celeste Simon, Ph.D. |
| 2:40 p.m. | Circulating Mesenchymal Progenitor Cells: Their Role in Pulmonary
Fibrosis and as Potential Progenitor Cells for Myofibroblasts
Robert Strieter, M.D. |
| 3:10 p.m. | Regulation of Centrosome Function by TSC1/TSC2 Aris Astrinidis, Ph.D. |
| 4:00 p.m. | Idiopathic Pulmonary Fibrosis: A Model for Benign Proliferative
Lung Disease
Victor Thannickal, M.D. |
| 4:30 p.m. | Cell Trafficking Defects Associated with Loss of Tuberin Function Ray Yeung, M.D. |
| Sunday, April 22 |
|
| 8:30 a.m. | Discussion for Future Directions for LAM Session Chair: Cheryl Walker, Ph.D., MD Anderson Cancer Center |
 |
|
 |